• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎感染的新兴治疗方法:批判性综述

Emerging Treatment Approaches for COVID-19 Infection: A Critical Review.

作者信息

Bharadwaj Alok, Kaur Rasanpreet, Gupta Saurabh

机构信息

Department of Biotechnology, GLA University, Mathura, 281406, UP, India.

出版信息

Curr Mol Med. 2024;24(4):435-448. doi: 10.2174/1566524023666230417112543.

DOI:10.2174/1566524023666230417112543
PMID:37070448
Abstract

In the present scenario, the SARS-CoV-2 virus has imposed enormous damage on human survival and the global financial system. It has been estimated that around 111 million people all around the world have been infected, and about 2.47 million people died due to this pandemic. The major symptoms were sneezing, coughing, cold, difficulty breathing, pneumonia, and multi-organ failure associated 1with SARS-CoV-2. Currently, two key problems, namely insufficient attempts to develop drugs against SARSCoV-2 and the lack of any biological regulating process, are mostly responsible for the havoc caused by this virus. Henceforth, developing a few novel drugs is urgently required to cure this pandemic. It has been noticed that the pathogenesis of COVID-19 is caused by two main events: infection and immune deficiency, that occur during the pathological process. Antiviral medication can treat both the virus and the host cells. Therefore, in the present review, the major approaches for the treatment have been divided into "target virus" and "target host" groups. These two mechanisms primarily rely on drug repositioning, novel approaches, and possible targets. Initially, we discussed the traditional drugs per the physicians' recommendations. Moreover, such therapeutics have no potential to fight against COVID-19. After that, detailed investigation and analysis were conducted to find some novel vaccines and monoclonal antibodies and conduct a few clinical trials to check their effectiveness against SARSCoV- 2 and mutant strains. Additionally, this study presents the most successful methods for its treatment, including combinatorial therapy. Nanotechnology was studied to build efficient nanocarriers to overcome the traditional constraints of antiviral and biological therapies.

摘要

在当前情况下,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒对人类生存和全球金融体系造成了巨大破坏。据估计,全球约有1.11亿人感染了该病毒,约247万人死于这场大流行。主要症状包括打喷嚏、咳嗽、感冒、呼吸困难、肺炎以及与SARS-CoV-2相关的多器官功能衰竭。目前,针对SARS-CoV-2研发药物的尝试不足以及缺乏任何生物调节过程这两个关键问题,是该病毒造成严重破坏的主要原因。因此,迫切需要研发几种新型药物来治愈这场大流行。已经注意到,2019冠状病毒病(COVID-19)的发病机制是由病理过程中发生的两个主要事件引起的:感染和免疫缺陷。抗病毒药物可以治疗病毒和宿主细胞。因此,在本综述中,主要的治疗方法分为“靶向病毒”和“靶向宿主”两类。这两种机制主要依赖于药物重新定位、新方法和可能的靶点。最初,我们按照医生的建议讨论了传统药物。此外,这类疗法没有对抗COVID-19的潜力。之后,进行了详细的调查和分析,以寻找一些新型疫苗和单克隆抗体,并进行了一些临床试验,以检验它们对SARS-CoV-2及其突变株的有效性。此外,本研究还介绍了最成功的治疗方法,包括联合治疗。研究了纳米技术以构建高效的纳米载体,以克服抗病毒和生物疗法的传统局限性。

相似文献

1
Emerging Treatment Approaches for COVID-19 Infection: A Critical Review.新型冠状病毒肺炎感染的新兴治疗方法:批判性综述
Curr Mol Med. 2024;24(4):435-448. doi: 10.2174/1566524023666230417112543.
2
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.重新利用现有药物治疗新型冠状病毒肺炎/严重急性呼吸综合征冠状病毒2感染:一项描述药物作用机制的综述
Biochem Pharmacol. 2021 Jan;183:114296. doi: 10.1016/j.bcp.2020.114296. Epub 2020 Oct 22.
3
Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to.新冠病毒治疗学:从计算到实践——我们现在在哪里,我们的前进方向在哪里。
Mol Divers. 2021 Feb;25(1):625-659. doi: 10.1007/s11030-020-10134-x. Epub 2020 Sep 2.
4
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
5
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.针对 COVID-19 的潜在再利用治疗药物和新型疫苗及其临床现状。
SLAS Discov. 2020 Dec;25(10):1097-1107. doi: 10.1177/2472555220945281. Epub 2020 Jul 21.
6
Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.重新定位药物以应对 COVID-19 大流行——一个洞察。
Curr Pharm Biotechnol. 2021;22(2):192-199. doi: 10.2174/1389201021999200820155927.
7
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.ACE2 受体的作用以及从恢复期血浆疗法到药物再利用治疗 COVID-19 的治疗选择全景。
Mol Cell Biochem. 2021 Feb;476(2):553-574. doi: 10.1007/s11010-020-03924-2. Epub 2020 Oct 7.
8
[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].[氯丙嗪在新冠病毒肺炎治疗中的重新应用:恢复研究]
Encephale. 2020 Jun;46(3S):S35-S39. doi: 10.1016/j.encep.2020.04.010. Epub 2020 Apr 29.
9
Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.基于 SARS-CoV-2 诱导的人呼吸道上皮细胞基因特征的综合荟萃分析的 COVID-19 药物再利用。
PLoS One. 2021 Sep 28;16(9):e0257784. doi: 10.1371/journal.pone.0257784. eCollection 2021.
10
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.重新利用药理学药物治疗 COVID-19 的潜力:文献综述。
Respir Res. 2021 Nov 27;22(1):304. doi: 10.1186/s12931-021-01885-8.

引用本文的文献

1
Assessment of Selected Biochemical Parameters of the Renin-Angiotensin-Aldosterone System in Repeat Convalescent Plasma Donors in the Context of Long-Term Changes Following SARS-CoV-2 Infection.在新冠病毒感染后的长期变化背景下,对重复恢复期血浆捐献者肾素-血管紧张素-醛固酮系统的选定生化参数进行评估。
J Clin Med. 2025 Jul 10;14(14):4910. doi: 10.3390/jcm14144910.

本文引用的文献

1
A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.对 SARS-CoV-2(COVID-19)复杂性、新兴变异体以及治疗干预和疫苗接种策略的批判性分析。
Biomed Pharmacother. 2022 Feb;146:112550. doi: 10.1016/j.biopha.2021.112550. Epub 2021 Dec 15.
2
COVID-19 challenges and its therapeutics.COVID-19 挑战及其治疗方法。
Biomed Pharmacother. 2021 Oct;142:112015. doi: 10.1016/j.biopha.2021.112015. Epub 2021 Aug 5.
3
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.
关于全球新冠疫苗研发努力的全面综述
ACS Cent Sci. 2021 Apr 28;7(4):512-533. doi: 10.1021/acscentsci.1c00120. Epub 2021 Mar 29.
4
Structure and function of SARS-CoV-2 polymerase.SARS-CoV-2 聚合酶的结构与功能。
Curr Opin Virol. 2021 Jun;48:82-90. doi: 10.1016/j.coviro.2021.03.010. Epub 2021 Apr 6.
5
Network medicine framework for identifying drug-repurposing opportunities for COVID-19.用于识别新冠病毒药物再利用机会的网络医学框架。
Proc Natl Acad Sci U S A. 2021 May 11;118(19). doi: 10.1073/pnas.2025581118.
6
Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.关于新冠疫苗可靠性与有效性的小型综述
Diagnostics (Basel). 2021 Mar 24;11(4):579. doi: 10.3390/diagnostics11040579.
7
Mutational analysis of structural proteins of SARS-CoV-2.新型冠状病毒结构蛋白的突变分析。
Heliyon. 2021 Mar;7(3):e06572. doi: 10.1016/j.heliyon.2021.e06572. Epub 2021 Mar 20.
8
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?抗2019冠状病毒病病毒疗法的最新进展:我们取得了多大的进展?
Front Pharmacol. 2021 Mar 8;12:632677. doi: 10.3389/fphar.2021.632677. eCollection 2021.
9
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.SARS-CoV-2 刺突蛋白的中和抗体逃逸:基于抗体的新冠病毒治疗和疫苗的风险评估。
Rev Med Virol. 2021 Nov;31(6):e2231. doi: 10.1002/rmv.2231. Epub 2021 Mar 16.
10
The first 12 months of COVID-19: a timeline of immunological insights.COVID-19 出现的头 12 个月:免疫学研究进展一览。
Nat Rev Immunol. 2021 Apr;21(4):245-256. doi: 10.1038/s41577-021-00522-1. Epub 2021 Mar 15.